Cann Global Past Earnings Performance
Past criteria checks 0/6
Cann Global's earnings have been declining at an average annual rate of -7.9%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been declining at an average rate of 4.9% per year.
Key information
-7.9%
Earnings growth rate
21.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | -4.9% |
| Return on equity | -95.6% |
| Net Margin | -1,461.4% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Cann Global makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 1 | -8 | 4 | 0 |
| 31 Mar 22 | 1 | -7 | 4 | 0 |
| 31 Dec 21 | 1 | -5 | 4 | 0 |
| 30 Sep 21 | 1 | -5 | 4 | 0 |
| 30 Jun 21 | 1 | -5 | 5 | 0 |
| 31 Mar 21 | 2 | -5 | 4 | 1 |
| 31 Dec 20 | 2 | -5 | 4 | 1 |
| 30 Sep 20 | 2 | -6 | 4 | 2 |
| 30 Jun 20 | 2 | -8 | 4 | 2 |
| 31 Mar 20 | 1 | -8 | 4 | 2 |
| 31 Dec 19 | 1 | -8 | 4 | 1 |
| 30 Sep 19 | 1 | -7 | 4 | 1 |
| 30 Jun 19 | 0 | -6 | 5 | 0 |
| 31 Mar 19 | 2 | -6 | 5 | 1 |
| 31 Dec 18 | 4 | -6 | 4 | 1 |
| 30 Sep 18 | 4 | -6 | 4 | 1 |
| 30 Jun 18 | 4 | -5 | 3 | 1 |
| 31 Mar 18 | 2 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -5 | 3 | 0 |
| 30 Sep 17 | 0 | -3 | 2 | 0 |
| 30 Jun 17 | 0 | -2 | 2 | 0 |
| 31 Mar 17 | 0 | -2 | 2 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
| 31 Mar 16 | 0 | -1 | 1 | 0 |
Quality Earnings: CGB is currently unprofitable.
Growing Profit Margin: CGB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CGB is unprofitable, and losses have increased over the past 5 years at a rate of 7.9% per year.
Accelerating Growth: Unable to compare CGB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).
Return on Equity
High ROE: CGB has a negative Return on Equity (-95.65%), as it is currently unprofitable.